CARsgen Presents Results on GPRC5D CAR-T CT071 in The Lancet Haematology - Thailand PR News - [Banking](https://thailandbusinessnews.net/category/banking/) - [Companies](https://thailandbusinessnews.net/category/companies/) - [Economy](https://thailandbusinessnews.net/category/economy/) - [Press Releases](https://thailandbusinessnews.net/category/press-release/) - [PR Newswire](https://thailandbusinessnews.net/pr-newswire-updates/) - [Tech](https://thailandbusinessnews.net/category/tech/) - [Tourism](https://thailandbusinessnews.net/category/tourism/) - [Press Release](https://thailandbusinessnews.net/category/press-release/) # CARsgen Presents Results on GPRC5D CAR-T CT071 in The Lancet Haematology ##### Up next ###### [Cebu Pacific Launches 10.10 Seat Sale for 2026 Getaways](https://thailandbusinessnews.net/press-release/cebu-pacific-launches-10-10-seat-sale-for-2026-getaways/) Published on 08 October 2025 ##### Author ##### [ CISION PRNewswire ](https://thailandbusinessnews.net/author/cision/) ##### Tags - [PRNewswire](https://thailandbusinessnews.net/tag/prnewswire/) ![](https://mma.prnasia.com/media2/1722549/Logo.jpg?p=medium600 "logo") SHANGHAI, Oct. 8, 2025 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the results of CT071 (an autologous CAR T-cell product targeting GPRC5D) for the treatment of relapsed/refractory multiple myeloma (R/R MM) in an investigator-initiated trial (NCT05838131) have been published in The Lancet Haematology. The article was titled "GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial". This trial aimed to assess the safety, preliminary activity of CT071 in R/R MM. 20 patients received CT071 infusion. Patients had received a median of 5 prior lines of therapy (IQR 3.0-6.5); 19 (95%) were double-class refractory, 13 (65%) were triple-class refractory, 5 (25%) were penta-drug refractory, 10 (50%) had received autologous stem cell transplantation (ASCT), and 5 (25%) had relapsed after CAR T-cell therapies targeting BCMA or BCMA/CD19. Four (20%) patients had extramedullary disease (EMD), 14 (70%) had ≥1 high-risk cytogenetics and 19 (95%) had a Revised International Staging System (R-ISS) 2 or 3 disease at baseline. No dose-limiting toxicities (DLTs) were observed. The recommended phase 2 dose was determined at 0.1×106 CAR T cells/kg. Cytokine release syndrome occurred in 12 patients (60%), all graded as 1 or 2. No Grade ≥3 cytokine release syndrome (CRS) occurred. One patient (5%) experienced Grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS). No treatment-related deaths occurred. With a median follow-up of 10.71 months (IQR 6.13-12.02), the objective response rate (ORR) was 100% (95%CI, 83.2-100). 10 (50%) patients achieved stringent complete response (sCR), 4 (20%) had very good partial response (VGPR) and 6 (30%) had partial response (PR). One patient with a large EMD (125 mm×99 mm at baseline) achieved a 67.6% reduction at month 10 with ongoing PR. All 5 patients previously treated with an anti-BCMA CAR T (n=1) or anti-BCMA/CD19 CAR T (n=4) responded; 2 achieved PR, 1 achieved VGPR and 2 achieved sCR. 18 of 20 (90%) evaluable patients achieved MRD negativity at 10−6 including all 10 with CR or sCR. Median time to MRD negativity was 29 days (IQR 29-29). Median duration of response (DoR), progression-free survival (PFS) and overall survival (OS) were not reached. The data cutoff for all analyses was December 9, 2024. About CT071CT071 is a CAR T-cell therapy candidate developed utilizing the proprietary CARcelerate® platform targeting GPRC5D for the treatment of relapsed/refractory multiple myeloma (R/R MM) or plasma cell leukemia (PCL). Initiated trials include an investigator-initiated trial for R/R MM or PCL in China (NCT05838131), and an investigator-initiated trial for newly diagnosed multiple myeloma (NDMM) in China (NCT06407947). About CARsgen Therapeutics Holdings LimitedCARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen’s mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable. Forward-looking StatementsAll statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group’s current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group’s control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading "Principal Risks and Uncertainties" in our most recent annual report and interim report and other announcements and reports made available on our corporate website, . No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release. [Source link ](https://www.prnasia.com/story/archive/4785243_CN85243_0?rand=89749) ``` This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network ``` ##### You May Also Like [](https://thailandbusinessnews.net/press-release/surfin-meta-digital-technology-signs-mou-with-the-philippine-social-security-system-to-explore-digital-financial-service-enhancements/) ![Surfin Meta Digital Technology signs MOU with the Philippine Social Security System to explore digital financial service enhancements](https://i0.wp.com/mma.prnasia.com/media2/2946589/image1.jpg?resize=260%2C140&ssl=1 "Surfin Meta Digital Technology signs MOU with the Philippine Social Security System to explore digital financial service enhancements") - [Press Release](https://thailandbusinessnews.net/category/press-release/) - [Tech](https://thailandbusinessnews.net/category/tech/) ## Surfin Meta Digital Technology signs MOU with the Philippine Social Security System to explore digital financial service enhancements DAVOS, Switzerland, April 1, 2026 /PRNewswire/ — The Philippines Social Security System… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - April 1, 2026 [](https://thailandbusinessnews.net/press-release/ascletis-announces-positive-interim-results-from-first-two-cohorts-of-u-s-phase-ib-multiple-ascending-dose-study-of-small-molecule-oral-glp-1r-agonist-asc30/) ## Ascletis Announces Positive Interim Results from First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 – ASC30 oral once-daily tablet demonstrated a 6.3% mean body weight reduction from… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - February 19, 2025 [](https://thailandbusinessnews.net/press-release/next-level-aviation-commences-recap-of-turning-rock-partners/) ## Next Level Aviation® Commences Recap of Turning Rock Partners NLA to complete the full redemption of Turning Rock’s preferred equity investment… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - January 14, 2025 ##### Most Read - [![Chubb Wealth Debuts Evergreen Private Markets Fund Series with S64](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/chubb-wealth-debuts-evergreen-private-markets-fund-series-with-s64/ "Chubb Wealth Debuts Evergreen Private Markets Fund Series with S64") [Chubb Wealth Debuts Evergreen Private Markets Fund Series with S64](https://thailandbusinessnews.net/press-release/chubb-wealth-debuts-evergreen-private-markets-fund-series-with-s64/ "Chubb Wealth Debuts Evergreen Private Markets Fund Series with S64") - [![Adecco Group announces Salesforce's Agentforce Coworker rollout across 40 countries](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/adecco-group-announces-salesforces-agentforce-coworker-rollout-across-40-countries/ "Adecco Group announces Salesforce's Agentforce Coworker rollout across 40 countries") [Adecco Group announces Salesforce's Agentforce Coworker rollout across 40 countries](https://thailandbusinessnews.net/press-release/adecco-group-announces-salesforces-agentforce-coworker-rollout-across-40-countries/ "Adecco Group announces Salesforce's Agentforce Coworker rollout across 40 countries") - [![JBD Launches the "Roadrunner" Platform: MicroLED Microdisplays with 2.5-μm Pixel Pitch](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/jbd-launches-the-roadrunner-platform-microled-microdisplays-with-2-5-%ce%bcm-pixel-pitch/ "JBD Launches the "Roadrunner" Platform: MicroLED Microdisplays with 2.5-μm Pixel Pitch") [JBD Launches the "Roadrunner" Platform: MicroLED Microdisplays with 2.5-μm Pixel Pitch](https://thailandbusinessnews.net/press-release/jbd-launches-the-roadrunner-platform-microled-microdisplays-with-2-5-%ce%bcm-pixel-pitch/ "JBD Launches the "Roadrunner" Platform: MicroLED Microdisplays with 2.5-μm Pixel Pitch") - [![INVT to Showcase Power and Liquid-Cooling Solutions for Data Center Modernization at Data Centre World Asia 2026](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/invt-to-showcase-power-and-liquid-cooling-solutions-for-data-center-modernization-at-data-centre-world-asia-2026/ "INVT to Showcase Power and Liquid-Cooling Solutions for Data Center Modernization at Data Centre World Asia 2026") [INVT to Showcase Power and Liquid-Cooling Solutions for Data Center Modernization at Data Centre World Asia 2026](https://thailandbusinessnews.net/press-release/invt-to-showcase-power-and-liquid-cooling-solutions-for-data-center-modernization-at-data-centre-world-asia-2026/ "INVT to Showcase Power and Liquid-Cooling Solutions for Data Center Modernization at Data Centre World Asia 2026") - [![Triton Uranium Advances Atlas Project, Reports Exploration Target of 46.56 Million Pounds of Uranium](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/triton-uranium-advances-atlas-project-reports-exploration-target-of-46-56-million-pounds-of-uranium/ "Triton Uranium Advances Atlas Project, Reports Exploration Target of 46.56 Million Pounds of Uranium") [Triton Uranium Advances Atlas Project, Reports Exploration Target of 46.56 Million Pounds of Uranium](https://thailandbusinessnews.net/press-release/triton-uranium-advances-atlas-project-reports-exploration-target-of-46-56-million-pounds-of-uranium/ "Triton Uranium Advances Atlas Project, Reports Exploration Target of 46.56 Million Pounds of Uranium") - [![Vietnam Emerges as ASEAN Growth Leader as Hiring Expands and AI Shapes Career Decisions, Reeracoen Survey Finds](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/vietnam-emerges-as-asean-growth-leader-as-hiring-expands-and-ai-shapes-career-decisions-reeracoen-survey-finds/ "Vietnam Emerges as ASEAN Growth Leader as Hiring Expands and AI Shapes Career Decisions, Reeracoen Survey Finds") [Vietnam Emerges as ASEAN Growth Leader as Hiring Expands and AI Shapes Career Decisions, Reeracoen Survey Finds](https://thailandbusinessnews.net/press-release/vietnam-emerges-as-asean-growth-leader-as-hiring-expands-and-ai-shapes-career-decisions-reeracoen-survey-finds/ "Vietnam Emerges as ASEAN Growth Leader as Hiring Expands and AI Shapes Career Decisions, Reeracoen Survey Finds") ##### Subscribe via Email Enter your email address to subscribe and receive notifications of new posts by email. Email Address Subscribe [](https://thailandbusinessnews.net/press-release/a-robust-adjusted-ebit-margin-of-18-8-driven-by-solid-organic-revenue-growth-of-7-4/) ![A robust adjusted EBIT margin of 18.8%, driven by solid organic revenue growth of 7.4%](https://i0.wp.com/mmx.prnasia.com/media/MS1988977/VBD_01.jpg?resize=260%2C140&ssl=1 "A robust adjusted EBIT margin of 18.8%, driven by solid organic revenue growth of 7.4%") ## A robust adjusted EBIT margin of 18.8%, driven by solid organic revenue growth of 7.4% PARIS, Sept. 18, 2026 /PRNewswire/ — Virbac Headquarters, Carros, France H1… [](https://thailandbusinessnews.net/press-release/tdh-holdings-announces-its-annual-general-meeting-of-shareholders-will-be-held-on-november-10-2026/) ## TDH Holdings Announces its Annual General Meeting of Shareholders will be Held on November 10, 2026 BEIJING, Sept. 18, 2026 /PRNewswire/ — TDH Holdings, Inc. (NASDAQ: PETZ)… [](https://thailandbusinessnews.net/press-release/advancion-releases-2025-sustainability-report-safe-by-choice-sustainable-by-design/) ## ADVANCION RELEASES 2025 SUSTAINABILITY REPORT: "SAFE BY CHOICE. SUSTAINABLE BY DESIGN." Advancion’s fifth annual report highlights the Company’s progress in… [](https://thailandbusinessnews.net/press-release/aml-rightsource-recognized-with-cobrasight-award-for-digital-asset-compliance-expertise/) ![AML RightSource Recognized with CobraSight Award for Digital Asset Compliance Expertise](https://i0.wp.com/mmx.prnasia.com/media/MS1556422/AML-RightSource-Logo.jpg?resize=260%2C140&ssl=1 "AML RightSource Recognized with CobraSight Award for Digital Asset Compliance Expertise") ## AML RightSource Recognized with CobraSight Award for Digital Asset Compliance Expertise Industry recognition highlights AML RightSource’s expertise in helping…